BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32804967)

  • 1. Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana.
    Manyeh AK; Ibisomi L; Ramaswamy R; Baiden F; Chirwa T
    PLoS Negl Trop Dis; 2020 Aug; 14(8):e0007009. PubMed ID: 32804967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using intervention mapping to design and implement quality improvement strategies towards elimination of lymphatic filariasis in Northern Ghana.
    Manyeh AK; Ibisomi L; Baiden F; Chirwa T; Ramaswamy R
    PLoS Negl Trop Dis; 2019 Mar; 13(3):e0007267. PubMed ID: 30908495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential factors influencing lymphatic filariasis transmission in "hotspot" and "control" areas in Ghana: the importance of vectors.
    Pi-Bansa S; Osei JHN; Frempong KK; Elhassan E; Akuoko OK; Agyemang D; Ahorlu C; Appawu MA; Koudou BG; Wilson MD; de Souza DK; Dadzie SK; Utzinger J; Boakye DA
    Infect Dis Poverty; 2019 Feb; 8(1):9. PubMed ID: 30717788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment.
    Ahorlu CSK; Koka E; Adu-Amankwah S; Otchere J; de Souza DK
    BMC Public Health; 2018 Feb; 18(1):238. PubMed ID: 29433461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent 'hotspots' of lymphatic filariasis microfilaraemia despite 14 years of mass drug administration in Ghana.
    Biritwum NK; Yikpotey P; Marfo BK; Odoom S; Mensah EO; Asiedu O; Alomatu B; Hervie ET; Yeboah A; Ade S; Hinderaker SG; Reid A; Takarinda KC; Koudou B; Koroma JB
    Trans R Soc Trop Med Hyg; 2016 Dec; 110(12):690-695. PubMed ID: 28938053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana.
    Biritwum NK; Garshong B; Alomatu B; de Souza DK; Gyapong M; Kyelem D
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005619. PubMed ID: 28493966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two 'Endgame' Districts in Indonesia Using Micronarrative Surveys.
    Krentel A; Damayanti R; Titaley CR; Suharno N; Bradley M; Lynam T
    PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005027. PubMed ID: 27812107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: The case of Luangwa District, Zambia.
    Silumbwe A; Halwindi H; Zulu JM
    PLoS Negl Trop Dis; 2019 Nov; 13(11):e0007861. PubMed ID: 31774820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress towards lymphatic filariasis elimination in Ghana from 2000-2016: Analysis of microfilaria prevalence data from 430 communities.
    Biritwum NK; Frempong KK; Verver S; Odoom S; Alomatu B; Asiedu O; Kontoroupis P; Yeboah A; Hervie ET; Marfo B; Boakye DA; de Vlas SJ; Gyapong JO; Stolk WA
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007115. PubMed ID: 31398203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating context-specific evidence-based quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana using the RE-AIM framework.
    Manyeh AK; Chirwa T; Ramaswamy R; Baiden F; Ibisomi L
    Trop Med Health; 2021 Feb; 49(1):16. PubMed ID: 33602322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved assessment of mass drug administration and health district management performance to eliminate lymphatic filariasis.
    Maroto-Camino C; Hernandez-Pastor P; Awaca N; Safari L; Hemingway J; Massangaie M; Whitson D; Jeffery C; Valadez JJ
    PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007337. PubMed ID: 31276494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of MDA registers for Lymphatic Filariasis: Findings, and potential uses in addressing the endgame elimination challenges.
    de Souza DK; Gass K; Otchere J; Htet YM; Asiedu O; Marfo B; Biritwum NK; Boakye DA; Ahorlu CS
    PLoS Negl Trop Dis; 2020 May; 14(5):e0008306. PubMed ID: 32407319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards elimination of lymphatic filariasis in southeastern Madagascar: Successes and challenges for interrupting transmission.
    Garchitorena A; Raza-Fanomezanjanahary EM; Mioramalala SA; Chesnais CB; Ratsimbasoa CA; Ramarosata H; Bonds MH; Rabenantoandro H
    PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006780. PubMed ID: 30222758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia.
    Krentel A; Wellings K
    Parasit Vectors; 2018 Mar; 11(1):179. PubMed ID: 29530082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling the cost of engage & treat and test & treat strategies towards the elimination of lymphatic filariasis in Ghana.
    Adams NNK; Ahorlu CS; de Souza DK; Aikins M
    PLoS Negl Trop Dis; 2024 May; 18(5):e0012213. PubMed ID: 38787898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-compliance to Mass Drug Administration Associated with the Low Perception of the Community Members About their Susceptibility to Lymphatic Filariasis in Ankobra, Ghana.
    Dicko I; Coulibaly YI; Sangaré M; Sarfo B; Nortey PA
    Infect Disord Drug Targets; 2020; 20(2):167-174. PubMed ID: 30727921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for lymphatic filariasis and mass drug administration non-participation in Mandalay Region, Myanmar.
    Dickson BFR; Graves PM; Aye NN; Nwe TW; Wai T; Win SS; Shwe M; Douglass J; Wood P; Wangdi K; McBride WJ
    Parasit Vectors; 2021 Jan; 14(1):72. PubMed ID: 33482891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping and modelling the impact of mass drug adminstration on filariasis prevalence in Myanmar.
    Aye NN; Lin Z; Lon KN; Linn NYY; Nwe TW; Mon KM; Ramaiah K; Betts H; Kelly-Hope LA
    Infect Dis Poverty; 2018 May; 7(1):56. PubMed ID: 29855355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strengthening of mass drug administration implementation is required to eliminate lymphatic filariasis from India: an evaluation study.
    Lahariya C; Mishra A
    J Vector Borne Dis; 2008 Dec; 45(4):313-20. PubMed ID: 19248659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination within reach: A cross-sectional study highlighting the factors that contribute to persistent lymphatic filariasis in eight communities in rural Ghana.
    Minetti C; Tettevi EJ; Mechan F; Prada JM; Idun B; Biritwum NK; Osei-Atweneboana MY; Reimer LJ
    PLoS Negl Trop Dis; 2019 Jan; 13(1):e0006994. PubMed ID: 30608931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.